FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...
NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...
NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic ...
FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...
NeoGenomics has seen a strong start to the year. The Fort Myers-based cancer testing and research lab reported revenue growth of 8% in the first quarter over the year. Revenue rose from roughly $156.2 ...
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...
Analyst Puneet Souda from Leerink Partners maintained a Buy rating on NeoGenomics (NEO – Research Report) and keeping the price target at $30.00. Puneet Souda has given his Buy rating due to a ...
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results